menu
Intellia Therapeutics Head office building

Press Releases

Intellia Therapeutics Names John Leonard, M.D., President and Chief Executive Officer

Dr. Leonard has successfully led the development and regulatory approval of breakthrough biopharmaceuticals Company’s pipeline continues to advance toward clinical development CAMBRIDGE, Mass. , Dec. 18, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc.
Read More

Intellia Therapeutics Announces New, Robust Genome Editing Data for Sickle Cell Disease at the American Society of Hematology Meeting

Data on ex vivo CRISPR/Cas9 genome-edited human hematopoietic stem cells shows increased production of fetal hemoglobin Approximately 80-95 percent editing was achieved in CD34+ cells Increased fetal hemoglobin levels were sustained for at least 16 weeks following transplant in mice ATLANTA , Dec.
Read More

Intellia Therapeutics to Present at November Healthcare Investor Conferences

CAMBRIDGE, Mass. , Nov. 02, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of curative therapeutics using CRISPR/Cas9 technology, will present at the following upcoming healthcare conferences in November: Tuesday,
Read More

Intellia Therapeutics Announces Pricing of Public Offering of Common Stock

CAMBRIDGE, Mass. , Nov. 01, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, today announced the pricing of an underwritten public offering of 6,250,000
Read More

Intellia Therapeutics Announces Proposed Public Offering of Common Stock

CAMBRIDGE, Mass. , Nov. 01, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, today announced that it has commenced an underwritten public offering of
Read More

Intellia Therapeutics Announces Third Quarter 2017 Financial Results

First company to demonstrate dose-dependent CRISPR/Cas9 liver editing in non-human primates, including editing of over 20 percent in certain animals, following systemic delivery of Intellia’s proprietary, non-viral, lipid nanoparticle delivery system Well-tolerated safety profile observed to date
Read More

Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2017 Earnings

CAMBRIDGE, Mass. , Oct. 30, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of curative therapeutics using CRISPR/Cas9 technology, will present third quarter 2017 results to investors and analysts in a conference call
Read More

Intellia Therapeutics to Present at October Healthcare Investor Conferences

CAMBRIDGE, Mass. , Oct. 03, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, will present at the following upcoming healthcare conferences in October:
Read More

Intellia Therapeutics Demonstrates Sustained and Durable Genome Editing with CRISPR/Cas9 in One-Year Animal Study

First-in-class, one-year data demonstrate sustained TTR protein reduction of approximately 97 percent, corresponding to 70 percent liver editing, following a single in vivo systemic dose in mice Non-human primate studies ongoing and leading to development candidate designation in first half 2018
Read More

Intellia Therapeutics to Present at Upcoming September Investor Healthcare Conferences

CAMBRIDGE, Mass. , Sept. 07, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, will present at key September investor healthcare conferences.
Read More
RSS FEEDS
PRINT PAGE